Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

84
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
84
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

109
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
109
Drug Discovery: Overview01:26

Drug Discovery: Overview

13.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

11.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.3K
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

84
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
84
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multi-modal co-attention model for accurate drug-target interaction prediction.

PloS one·2026
Same author

Association between urinary heavy metals, phthalates, phytoestrogens, and polycyclic aromatic hydrocarbons and endometriosis: A cross-sectional study from NHANES 1999 to 2016.

Medicine·2026
Same author

OSBPL3 promotes colorectal cancer progression through modulation of TGF-β signaling and immune cell infiltration.

Translational cancer research·2026
Same author

CCPD under sparsity and low-rank constraints: multi-frequency dynamic functional network connectivity analysis in schizophrenia.

Frontiers in neuroscience·2026
Same author

Core regulatory mechanisms of the PD-L1 axis and clinical strategies for immune escape and immunotherapy response in nasopharyngeal carcinoma.

Translational oncology·2026
Same author

External and internal exposure to PM<sub>2.5</sub>-bound PAHs from household solid fuel combustion: health effects mediated by urinary metabolites.

Environmental pollution (Barking, Essex : 1987)·2026

Related Experiment Video

Updated: Apr 1, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

TriCloud: Drug-Target-Disease Ternary Network for Drug Repositioning Research Based on Point Cloud Modeling.

Xiwei Tang, Wanjun Ma, Anzheng Gao

    IEEE Transactions on Computational Biology and Bioinformatics
    |March 30, 2026
    PubMed
    Summary

    TriCloud, a novel point cloud modeling approach, enhances drug-target-disease prediction by avoiding graph structures. This method significantly improves accuracy for drug repurposing and precision medicine applications.

    More Related Videos

    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
    03:08

    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

    Published on: October 3, 2025

    1.1K
    Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
    13:18

    Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

    Published on: March 3, 2023

    1.9K

    Related Experiment Videos

    Last Updated: Apr 1, 2026

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    10.3K
    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
    03:08

    Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

    Published on: October 3, 2025

    1.1K
    Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
    13:18

    Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

    Published on: March 3, 2023

    1.9K

    Area of Science:

    • Computational biology
    • Bioinformatics
    • Drug discovery

    Background:

    • Drug-target-disease associations are complex and data-scarce.
    • Existing graph-based methods suffer information loss and struggle with long-range dependencies.
    • This limits the effectiveness of computational models in predicting these relationships.

    Purpose of the Study:

    • To introduce TriCloud, a novel method for modeling drug-target-disease associations using point cloud techniques.
    • To overcome the limitations of explicit graph construction in capturing complex relationships.
    • To improve the performance and reliability of computational drug repurposing frameworks.

    Main Methods:

    • Representing drug-target-disease triplets as spatial point clouds.
    • Utilizing a PointNet-based architecture for direct feature learning on unordered point sets.
    • Implementing a multi-view feature extraction and fusion mechanism for enhanced structural modeling.

    Main Results:

    • TriCloud significantly outperforms existing methods on benchmark datasets, achieving superior AUC and AUPR scores.
    • Achieved an Area Under the Curve (AUC) of 0.9995 and an Area Under the Precision-Recall Curve (AUPR) of 0.9996.
    • Demonstrated excellent generalization ability through external validation and identified geometric-semantic joint features as crucial for classification.

    Conclusions:

    • TriCloud offers an efficient and reliable computational framework for drug repurposing.
    • The point cloud modeling approach effectively captures complex geometric and topological relationships.
    • This work contributes to advancing precision medicine through improved drug discovery tools.